Table 1 Characteristics of the study population
From: HbA1c as screening for gestational diabetes mellitus in women with polycystic ovary syndrome
Characteristic | N | Median (min-max) or n (%) |
|---|---|---|
Age (years) | 228 | 30 (19-44) |
BMI (kg/m2) | 228 | 27.3 (18.8-50.2) |
Caucasian (no.) | 228 | 221 (96.9 %) |
GDM in previous pregnancy (no.) | 228 | 10 (4.4 %) |
Preeclampsia in previous pregnancy (no.) | 228 | 8 (3.5 %) |
Pregestational hypertension (no.) | 227 | 11 (4.9 %) |
Smoking in first trimester (no.) | 227 | 16 (7.1 %) |
Nulliparity (no.) | 228 | 132 (58 %) |
Metformin use at conception (no.) | 228 | 73 (32 %) |
Randomised to metformin (no.) | 228 | 114 (50 %) |
Preeclampsia (no.) | 228 | 14 (6.1 %) |
Birth weight (g) | 227 | 3550 (165-4840) |
HbA1c in first trimester (%, (mmol/mol)) | 228 | 5.1 (4.6-6.6) (32 (27-49)) |
Fasting glucose in first trimester (mmol/L) | 228 | 4.6 (3.4-6.6) |
2-h glucose in first trimester (mmol/L) | 226 | 5.4 (2.5-10.4) |
Fasting glucose in gestational week 19 (mmol/L) | 213 | 4.3 (3.4-6.6) |
2-h glucose in gestational week 19 (mmol/L) | 198 | 5.7 (2.4-10.7) |
Fasting glucose in gestational week 32 (mmol/L) | 202 | 4.4 (3.1-9.4) |
2-h glucose in gestational week 32 (mmol/L) | 177 | 6.2 (2.5-9.8) |
Fasting glucose in gestational week 36 (mmol/L) | 194 | 4.3 (3.4-9.2) |